Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/aps.2015.91 http://scihub22266oqcxt.onion/10.1038/aps.2015.91 C4816237!4816237 !26592511     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26592511 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Acta+Pharmacol+Sin 2015 ; 36 (12 ): 1395-407 Nephropedia Template TP {{tp|p=26592511 |t=2015. Toll-like receptors: potential targets for lupus treatment |pdf=|usr=}}{{26592511 }} gab.com Text Toll-like receptors: potential targets for lupus treatment JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=26592511 #FOAvip Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the loss of tolerance to self-nuclear antigens. Accumulating evidence shows that Toll-like receptors (TLRs), previously proven to be critical for host defense, are implicated in the pathogenesis of autoimmune diseases by recognition of self-molecules. Genome-wide association studies, experimental mouse models and clinical sample studies have provided evidence for the involvement of TLRs, including TLR2/4, TLR5, TLR3 and TLR7/8/9, in SLE pathogenesis. A number of downstream proteins in the TLR signaling cascade (such as MyD88, IRAKs and IFN-?) are identified as potential therapeutic targets for SLE treatment. Numerous antagonists targeting TLR signaling, including oligonucleotides, small molecular inhibitors and antibodies, are currently under preclinical studies or clinical trials for SLE treatment. Moreover, the emerging new manipulation of TLR signaling by microRNA (miRNA) regulation shows promise for the future treatment of SLE. Twit Text FOAVip Toll-like receptors: potential targets for lupus treatment ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=26592511 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26592511 #FOAvip English Wikipedia <ref>{{Cite pmid|26592511 }}</ref> Toll-like receptors: potential targets for lupus treatment #MMPMID26592511 Wu YW ; Tang W ; Zuo JP Acta Pharmacol Sin 2015[Dec]; 36 (12 ): 1395-407 PMID26592511 show ga Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the loss of tolerance to self-nuclear antigens. Accumulating evidence shows that Toll-like receptors (TLRs), previously proven to be critical for host defense, are implicated in the pathogenesis of autoimmune diseases by recognition of self-molecules. Genome-wide association studies, experimental mouse models and clinical sample studies have provided evidence for the involvement of TLRs, including TLR2/4, TLR5, TLR3 and TLR7/8/9, in SLE pathogenesis. A number of downstream proteins in the TLR signaling cascade (such as MyD88, IRAKs and IFN-?) are identified as potential therapeutic targets for SLE treatment. Numerous antagonists targeting TLR signaling, including oligonucleotides, small molecular inhibitors and antibodies, are currently under preclinical studies or clinical trials for SLE treatment. Moreover, the emerging new manipulation of TLR signaling by microRNA (miRNA) regulation shows promise for the future treatment of SLE. |Animals [MESH] |Antibodies/therapeutic use [MESH] |Drug Discovery/*methods [MESH] |Humans [MESH] |Lupus Erythematosus, Systemic/*drug therapy/*immunology/pathology [MESH] |MicroRNAs/therapeutic use [MESH] |Molecular Targeted Therapy/*methods [MESH] |Oligonucleotides/therapeutic use [MESH] |Signal Transduction/drug effects [MESH] |Small Molecule Libraries/therapeutic use [MESH]Toll-like receptors: potential targets for lupus treatment (epmc).pdf DeepDyve Pubget Overpricing